{"id":"W4404940529","doi":"10.1038/s41375-024-02487-1","title":"Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia","year":2024,"lang":"en","type":"erratum","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Obinutuzumab; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Internal medicine; Oncology; Leukemia; Cancer research; Immunology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007308573,0.00215394,0.002012776,0.00305103,0.002123454,0.003152432,0.003352915,0.006516261,0.04335641],"category_scores_gemma":[0.1022766,0.001301487,0.002141783,0.002554524,0.001754627,0.001707489,0.001266624,0.009584787,0.02244858],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003987738,"about_ca_system_score_gemma":0.006289994,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02425461,"about_ca_topic_score_gemma":0.01995316,"domain_scores_codex":[0.9938262,0.001189397,0.001398374,0.0007058636,0.002456516,0.0004236088],"domain_scores_gemma":[0.957965,0.01645099,0.002594375,0.002172219,0.01951646,0.001301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005345096,0.000004220256,0.00006520413,0.000108045,0.00001843504,0.0001822165,0.0000159382,0.00003198742,0.00002740568,0.0003041897,0.9956678,0.003521081],"study_design_scores_gemma":[0.0003134468,0.00004619114,0.001286027,0.001024073,0.0001839958,0.001704637,0.00006489837,0.0004604176,0.0005120566,0.001992517,0.9923379,0.00007381929],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0002872489,0.001283286,0.0009772121,0.08949026,0.8990408,0.00005745716,0.005272571,0.0005470571,0.003044163],"genre_scores_gemma":[0.02495992,0.01234641,0.01020074,0.2533704,0.4784972,0.0005667857,0.01304717,0.003687841,0.2033235],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.04335641,"threshold_uncertainty_score":0.1450416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03698168111577174,"score_gpt":0.313390055003235,"score_spread":0.2764083738874633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}